Top

Published in:

01-04-2014 | Original Article

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation

Authors: M. Gierth, H. M. Fritsche, H. Buchner, M. May, A. Aziz, W. Otto, C. Bolenz, L. Trojan, E. Hermann, A. Tiemann, S. C. Müller, J. Ellinger, S. Brookman-May, C. G. Stief, D. Tilki, P. Nuhn, T. Höfner, M. Hohenfellner, A. Haferkamp, J. Roigas, M. Zacharias, W. F. Wieland, H. Riedmiller, S. Denzinger, P. J. Bastian, M. Burger

Published in: World Journal of Urology | Issue 2/2014

Abstract

Purpose

Radical cystectomy (RC) and pelvic lymph node dissection (LND) are standard treatments for muscle-invasive urothelial carcinoma of the bladder. Lymph node staging is a prerequisite for clinical decision-making regarding adjuvant chemotherapy and follow-up regimens. Recently, the clinical and pathological nodal staging scores (cNSS and pNSS) were developed. Prior to RC, cNSS determines the minimum number of lymph nodes required to be dissected; pNSS quantifies the accuracy of negative nodal staging based on pT stage and dissected LNs. cNSS and pNSS have not been externally validated, and their relevance for prediction of cancer-specific mortality (CSM) has not been assessed.

Methods

In this retrospective study of 2,483 RC patients from eight German centers, we externally validated cNSS and pNSS and determined their prediction of CSM. All patients underwent RC and LND. Median follow-up was 44 months. cNSS and pNSS sensitivities were evaluated using the original beta-binominal models. Adjusted proportional hazards models were calculated for pN0 patients to assess the predictive value of cNSS and pNSS for CSM.

Results

cNSS and pNSS both pass external validation. Adjusted for other clinical parameters, cNSS can predict outcome after RC. pNSS has no independent impact on prediction of CSM. The retrospective design is the major limitation of the study.

Conclusions

In the present external validation, we confirm the validity of both cNSS and pNSS. cNSS is an independent predictor of CSM, thus rendering it useful as a tool for planning the extent of LND.

Heidenreich A (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymphadenectomy: optimizing a risk-adapted surgical approach. Eur Urol 61:488–490PubMedCrossRef

Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487PubMedCrossRef

Rink M, Shariat SF (2012) Can we apply nomograms derived in the United States to European patients? Yes, we can! Eur Urol 61:65–66PubMedCrossRef

Kutikov A, Smaldone MC, Egleston BL et al (2011) Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 60:241–248PubMedCentralPubMedCrossRef

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241

Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018PubMedCrossRef

Sylvester RJ (2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 60: 431–433 (discussion 433–444)

Nuhn P, May M, Sun M et al (2012) External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol 61:58–64PubMedCrossRef

Zaak D, Burger M, Otto W et al (2010) Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 106:342–348PubMedCrossRef

10.

May M, Herrmann E, Bolenz C et al (2011) Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 18:2018–2025PubMedCrossRef

11.

Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G (2004) Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol 172:1286–1290PubMedCrossRef

12.

Capitanio U, Suardi N, Shariat SF et al (2009) Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int 103:1359–1362PubMedCrossRef

13.

Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF (2002) Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167:1295–1298PubMedCrossRef

14.

Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH (2006) Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107:2368–2374PubMedCrossRef

15.

Konety BR, Joslyn SA, O’Donnell MA (2003) Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the surveillance, epidemiology and end results program data base. J Urol 169:946–950PubMedCrossRef

16.

Shariat SF, Ehdaie B, Rink M, et al (2012) Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 61:237–42

17.

Shariat SF, Rink M, Ehadaie B et al (2013) Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol 63:371–378

18.

Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 59:997–1008

19.

Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C, European Association of Urology (EAU) Working Group on Oncological Urology (2002) Guidelines on bladder cancer. Eur Urol 41:105–112PubMedCrossRef

20.

Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef

21.

Roth B, Wissmeyer MP, Zehnder P et al (2010) A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol 57:205–211PubMedCrossRef

22.

Zehnder P, Studer UE, Skinner EC et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186:1261–1268PubMedCrossRef

23.

Studer UE, Sylvester R, Re: Shahrokh F. Shariat, Behfar Ehdaie, Michael Rink, et al (2012) Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 61:237–242.

24.

Steven K, Poulsen AL (2007) Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 178: 1218–1223 (discussion 1223–1224)

25.

Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher M, Studer UE et al. (2008) Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 179: 873–878 (discussion 878)

26.

Meijer RP, Nunnink CJ, Wassenaar AE et al (2012) Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. J Urol 187:446–450PubMedCrossRef

27.

Fleischmann A, Thalmann GN, Markwaldert R, Studer UE (2005) Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 23:2358–2365PubMedCrossRef

28.

Thurairaja R, Studer UE, Burkhard FC (2009) Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist 14:40–51PubMedCrossRef

29.

Zlotta AR (2012) Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: what should we perform? Eur Urol 61:243–244PubMedCrossRef

30.

Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309PubMedCrossRef

Title: Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation
Authors: M. Gierth
H. M. Fritsche
H. Buchner
M. May
A. Aziz
W. Otto
C. Bolenz
L. Trojan
E. Hermann
A. Tiemann
S. C. Müller
J. Ellinger
S. Brookman-May
C. G. Stief
D. Tilki
P. Nuhn
T. Höfner
M. Hohenfellner
A. Haferkamp
J. Roigas
M. Zacharias
W. F. Wieland
H. Riedmiller
S. Denzinger
P. J. Bastian
M. Burger
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1105-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Quantification of median lobe protrusion and its impact on the base surgical margin status during robot-assisted laparoscopic prostatectomy

A learning curve assessment of real-time sonoelastography of the prostate

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort

Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer

Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy